|
WO2020236839A2
|
|
Generation of protein sequences using machine learning techniques
|
|
WO2020168225A2
|
|
Facilities and processes to produce biotherapeutics
|
|
US2020003714A1
|
|
High throughput interrogation of physiochemical properties of a protein
|
|
US2019346456A1
|
|
High throughput antibody variant screening method
|
|
WO2019165476A1
|
|
Determining protein structure and properties based on sequence
|
|
US2019185881A1
|
|
Inducible expression from transposon-based vectors and uses
|
|
US2020411136A1
|
|
Determining impact on properties of proteins based on amino acid sequence modifications
|
|
US2019185863A1
|
|
Expression from transposon-based vectors and uses
|
|
EP3755447A1
|
|
Determining conditions for purification of proteins
|
|
WO2019099965A1
|
|
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
WO2019036626A1
|
|
Method of purifying glycosylated protein from host cell galectins and other contaminants
|
|
WO2018227167A1
|
|
Predicting molecular properties of molecular variants using residue-specific molecular structural features
|
|
US2019298801A1
|
|
Aflibercept formulations and uses thereof
|
|
WO2017132376A1
|
|
Hybrid promoter and uses thereof
|
